Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 13;146(5):1445–1456. doi: 10.1002/ijc.32586

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

ctDNA dynamics in four individual patients during follow‐up. (a) Tumor volumes, CA19.9 and ctDNA VAF all showed similar dynamics. (b) CA19.9 and ctDNA VAF showed opposite responses in relatively stable tumor volume. (c) While VAF and CA19.9 showed similar trends in this patient, tumor volume differed. NB: One follow‐up measurement showed a KRAS VAF of 76%, indicating amplification of KRAS. The measurement was confirmed with ddPCR and observed again in the consecutive sample collected 2 weeks later (no treatment was started in the interval). (d) ctDNA and CA19.9 showed similar trends. Abbreviations: PD, progressive disease; PR, partial response; SD, stable disease; all according to RECIST 1.1. In the lower parts of the figures (illustrations), 3D tumor volumes are shown in green. The left and right Y‐axes represent different parameters in per subfigure, as the absolute values of the three parameter (ctDNA, CA19.9, tumor volumes) differed widely.